In accordance with the prophylactic models, treatment with placental gp96-pulsed BMDCs significantly inhibited B16-F10 (Fig 4B, P<0.001) and LLC (Fig 4D, P<0.01) tumor growth and improved mouse survival (Fig 4C and 4E, P<0.01 for B16-F10 and P<0.05 for LLC) compared with liver gp96-pulsed BMDCs. This evidence concerns the gene HSP90B1 and neoplasm.